 | • レポートコード：GIR201115570 • 出版社/出版日：GlobalInfoResearch / 2020年10月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、122ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、HER2陽性乳がんの世界市場を調査対象にし、HER2陽性乳がんの市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（Grifola Frondosa、外科、放射線及び化学療法、内分泌療法、分子標的療法）、用途別分析（病院、スペシャリストクリニック、バイオテクノロジー及び製薬会社、研究及び学術機関、その他）、市場予測（2021年～2025年）情報などを整理しました。 ・市場概要 ・企業情報：Pfizer (Pharmacia and Upjohn Company)、Odonate Therapeutics、Eli Lilly、Novartis、Jiangsu HengRui Medicine、AstraZeneca Pharmaceuticals、Immunomedics、Merck、Roche Group、Radius Pharmaceuticals、GlaxoSmithKline、Syndax Pharmaceuticals、Millennium Pharmaceuticals、Merrimack Pharmaceuticals、Bayer、Eagle Pharmaceuticals ・企業別売上、市場シェア ・HER2陽性乳がんの地域別市場分析 ・HER2陽性乳がんの北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・HER2陽性乳がんのヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・HER2陽性乳がんのアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・HER2陽性乳がんの南米市場規模2015-2020：ブラジル、アルゼンチンなど ・HER2陽性乳がんの中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・HER2陽性乳がんの種類別市場規模2015-2020：Grifola Frondosa、外科、放射線及び化学療法、内分泌療法、分子標的療法 ・HER2陽性乳がんの用途別市場規模2015-2020：病院、スペシャリストクリニック、バイオテクノロジー及び製薬会社、研究及び学術機関、その他 ・HER2陽性乳がんの世界市場予測2021-2025：地域別、種類別、用途別 ・調査の結果・結論 |
Market Overview
The global HER2-Positive Breast Cancer market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The HER2-Positive Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
HER2-Positive Breast Cancer market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, HER2-Positive Breast Cancer market has been segmented into:
Grifola Frondosa
Surgery
Radiation and Chemotherapy
Endocrine Therapy
Molecular Targeted Therapy
By Application, HER2-Positive Breast Cancer has been segmented into:
Hospital
Specialist Clinic
Biotechnology and Pharmaceutical Companies
Research and Academic Institutions
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global HER2-Positive Breast Cancer market presented in the report. This section sheds light on the sales growth of different regional and country-level HER2-Positive Breast Cancer markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global HER2-Positive Breast Cancer market.
The report offers in-depth assessment of the growth and other aspects of the HER2-Positive Breast Cancer market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and HER2-Positive Breast Cancer Market Share Analysis
HER2-Positive Breast Cancer competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, HER2-Positive Breast Cancer sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the HER2-Positive Breast Cancer sales, revenue and market share for each player covered in this report.
The major players covered in HER2-Positive Breast Cancer are:
Pfizer (Pharmacia and Upjohn Company)
Odonate Therapeutics
Eli Lilly
Novartis
Jiangsu HengRui Medicine
AstraZeneca Pharmaceuticals
Immunomedics
Merck
Roche Group
Radius Pharmaceuticals
GlaxoSmithKline
Syndax Pharmaceuticals
Millennium Pharmaceuticals
Merrimack Pharmaceuticals
Bayer
Eagle Pharmaceuticals
Table of Contents
1 HER2-Positive Breast Cancer Market Overview
1.1 Product Overview and Scope of HER2-Positive Breast Cancer
1.2 Classification of HER2-Positive Breast Cancer by Type
1.2.1 Global HER2-Positive Breast Cancer Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global HER2-Positive Breast Cancer Revenue Market Share by Type in 2019
1.2.3 Grifola Frondosa
1.2.4 Surgery
1.2.5 Radiation and Chemotherapy
1.2.6 Endocrine Therapy
1.2.7 Molecular Targeted Therapy
1.3 Global HER2-Positive Breast Cancer Market by Application
1.3.1 Overview: Global HER2-Positive Breast Cancer Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Specialist Clinic
1.3.4 Biotechnology and Pharmaceutical Companies
1.3.5 Research and Academic Institutions
1.3.6 Other
1.4 Global HER2-Positive Breast Cancer Market by Regions
1.4.1 Global HER2-Positive Breast Cancer Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of HER2-Positive Breast Cancer (2015-2025)
1.4.3 North America (USA, Canada and Mexico) HER2-Positive Breast Cancer Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) HER2-Positive Breast Cancer Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) HER2-Positive Breast Cancer Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) HER2-Positive Breast Cancer Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) HER2-Positive Breast Cancer Status and Prospect (2015-2025)
2 Company Profiles
2.1 Pfizer (Pharmacia and Upjohn Company)
2.1.1 Pfizer (Pharmacia and Upjohn Company) Details
2.1.2 Pfizer (Pharmacia and Upjohn Company) Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer (Pharmacia and Upjohn Company) SWOT Analysis
2.1.4 Pfizer (Pharmacia and Upjohn Company) Product and Services
2.1.5 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.2 Odonate Therapeutics
2.2.1 Odonate Therapeutics Details
2.2.2 Odonate Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Odonate Therapeutics SWOT Analysis
2.2.4 Odonate Therapeutics Product and Services
2.2.5 Odonate Therapeutics HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.3 Eli Lilly
2.3.1 Eli Lilly Details
2.3.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Eli Lilly SWOT Analysis
2.3.4 Eli Lilly Product and Services
2.3.5 Eli Lilly HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.5 Jiangsu HengRui Medicine
2.5.1 Jiangsu HengRui Medicine Details
2.5.2 Jiangsu HengRui Medicine Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Jiangsu HengRui Medicine SWOT Analysis
2.5.4 Jiangsu HengRui Medicine Product and Services
2.5.5 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.6 AstraZeneca Pharmaceuticals
2.6.1 AstraZeneca Pharmaceuticals Details
2.6.2 AstraZeneca Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 AstraZeneca Pharmaceuticals SWOT Analysis
2.6.4 AstraZeneca Pharmaceuticals Product and Services
2.6.5 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.7 Immunomedics
2.7.1 Immunomedics Details
2.7.2 Immunomedics Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Immunomedics SWOT Analysis
2.7.4 Immunomedics Product and Services
2.7.5 Immunomedics HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Merck SWOT Analysis
2.8.4 Merck Product and Services
2.8.5 Merck HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.9 Roche Group
2.9.1 Roche Group Details
2.9.2 Roche Group Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Roche Group SWOT Analysis
2.9.4 Roche Group Product and Services
2.9.5 Roche Group HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.10 Radius Pharmaceuticals
2.10.1 Radius Pharmaceuticals Details
2.10.2 Radius Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Radius Pharmaceuticals SWOT Analysis
2.10.4 Radius Pharmaceuticals Product and Services
2.10.5 Radius Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 GlaxoSmithKline SWOT Analysis
2.11.4 GlaxoSmithKline Product and Services
2.11.5 GlaxoSmithKline HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.12 Syndax Pharmaceuticals
2.12.1 Syndax Pharmaceuticals Details
2.12.2 Syndax Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Syndax Pharmaceuticals SWOT Analysis
2.12.4 Syndax Pharmaceuticals Product and Services
2.12.5 Syndax Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.13 Millennium Pharmaceuticals
2.13.1 Millennium Pharmaceuticals Details
2.13.2 Millennium Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Millennium Pharmaceuticals SWOT Analysis
2.13.4 Millennium Pharmaceuticals Product and Services
2.13.5 Millennium Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.14 Merrimack Pharmaceuticals
2.14.1 Merrimack Pharmaceuticals Details
2.14.2 Merrimack Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Merrimack Pharmaceuticals SWOT Analysis
2.14.4 Merrimack Pharmaceuticals Product and Services
2.14.5 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.15 Bayer
2.15.1 Bayer Details
2.15.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Bayer SWOT Analysis
2.15.4 Bayer Product and Services
2.15.5 Bayer HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.16 Eagle Pharmaceuticals
2.16.1 Eagle Pharmaceuticals Details
2.16.2 Eagle Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Eagle Pharmaceuticals SWOT Analysis
2.16.4 Eagle Pharmaceuticals Product and Services
2.16.5 Eagle Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global HER2-Positive Breast Cancer Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 HER2-Positive Breast Cancer Players Market Share
3.2.2 Top 10 HER2-Positive Breast Cancer Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global HER2-Positive Breast Cancer Revenue and Market Share by Regions
4.2 North America HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
4.3 Europe HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
4.5 South America HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
5 North America HER2-Positive Breast Cancer Revenue by Countries
5.1 North America HER2-Positive Breast Cancer Revenue by Countries (2015-2020)
5.2 USA HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
5.3 Canada HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
5.4 Mexico HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
6 Europe HER2-Positive Breast Cancer Revenue by Countries
6.1 Europe HER2-Positive Breast Cancer Revenue by Countries (2015-2020)
6.2 Germany HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
6.3 UK HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
6.4 France HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
6.5 Russia HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
6.6 Italy HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
7 Asia-Pacific HER2-Positive Breast Cancer Revenue by Countries
7.1 Asia-Pacific HER2-Positive Breast Cancer Revenue by Countries (2015-2020)
7.2 China HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
7.3 Japan HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
7.4 Korea HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
7.5 India HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
8 South America HER2-Positive Breast Cancer Revenue by Countries
8.1 South America HER2-Positive Breast Cancer Revenue by Countries (2015-2020)
8.2 Brazil HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
8.3 Argentina HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue HER2-Positive Breast Cancer by Countries
9.1 Middle East & Africa HER2-Positive Breast Cancer Revenue by Countries (2015-2020)
9.2 Saudi Arabia HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
9.3 UAE HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
9.4 Egypt HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
9.5 South Africa HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global HER2-Positive Breast Cancer Revenue and Market Share by Type (2015-2020)
10.2 Global HER2-Positive Breast Cancer Market Forecast by Type (2019-2024)
10.3 Grifola Frondosa Revenue Growth Rate (2015-2025)
10.4 Surgery Revenue Growth Rate (2015-2025)
10.5 Radiation and Chemotherapy Revenue Growth Rate (2015-2025)
10.6 Endocrine Therapy Revenue Growth Rate (2015-2025)
10.7 Molecular Targeted Therapy Revenue Growth Rate (2015-2025)
11 Global HER2-Positive Breast Cancer Market Segment by Application
11.1 Global HER2-Positive Breast Cancer Revenue Market Share by Application (2015-2020)
11.2 HER2-Positive Breast Cancer Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Specialist Clinic Revenue Growth (2015-2020)
11.5 Biotechnology and Pharmaceutical Companies Revenue Growth (2015-2020)
11.6 Research and Academic Institutions Revenue Growth (2015-2020)
11.7 Other Revenue Growth (2015-2020)
12 Global HER2-Positive Breast Cancer Market Size Forecast (2021-2025)
12.1 Global HER2-Positive Breast Cancer Market Size Forecast (2021-2025)
12.2 Global HER2-Positive Breast Cancer Market Forecast by Regions (2021-2025)
12.3 North America HER2-Positive Breast Cancer Revenue Market Forecast (2021-2025)
12.4 Europe HER2-Positive Breast Cancer Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific HER2-Positive Breast Cancer Revenue Market Forecast (2021-2025)
12.6 South America HER2-Positive Breast Cancer Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa HER2-Positive Breast Cancer Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global HER2-Positive Breast Cancer Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of HER2-Positive Breast Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global HER2-Positive Breast Cancer Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market HER2-Positive Breast Cancer Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Pfizer (Pharmacia and Upjohn Company) Corporate Information, Location and Competitors
Table 6. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Major Business
Table 7. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 8. Pfizer (Pharmacia and Upjohn Company) SWOT Analysis
Table 9. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product and Solutions
Table 10. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Odonate Therapeutics Corporate Information, Location and Competitors
Table 12. Odonate Therapeutics HER2-Positive Breast Cancer Major Business
Table 13. Odonate Therapeutics HER2-Positive Breast Cancer Total Revenue (USD Million) (2018-2019)
Table 14. Odonate Therapeutics SWOT Analysis
Table 15. Odonate Therapeutics HER2-Positive Breast Cancer Product and Solutions
Table 16. Odonate Therapeutics HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Eli Lilly Corporate Information, Location and Competitors
Table 18. Eli Lilly HER2-Positive Breast Cancer Major Business
Table 19. Eli Lilly HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 20. Eli Lilly SWOT Analysis
Table 21. Eli Lilly HER2-Positive Breast Cancer Product and Solutions
Table 22. Eli Lilly HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Novartis Corporate Information, Location and Competitors
Table 24. Novartis HER2-Positive Breast Cancer Major Business
Table 25. Novartis HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 26. Novartis SWOT Analysis
Table 27. Novartis HER2-Positive Breast Cancer Product and Solutions
Table 28. Novartis HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Jiangsu HengRui Medicine Corporate Information, Location and Competitors
Table 30. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Major Business
Table 31. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 32. Jiangsu HengRui Medicine SWOT Analysis
Table 33. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product and Solutions
Table 34. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. AstraZeneca Pharmaceuticals Corporate Information, Location and Competitors
Table 36. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Major Business
Table 37. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 38. AstraZeneca Pharmaceuticals SWOT Analysis
Table 39. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions
Table 40. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Immunomedics Corporate Information, Location and Competitors
Table 42. Immunomedics HER2-Positive Breast Cancer Major Business
Table 43. Immunomedics HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 44. Immunomedics SWOT Analysis
Table 45. Immunomedics HER2-Positive Breast Cancer Product and Solutions
Table 46. Immunomedics HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Merck Corporate Information, Location and Competitors
Table 48. Merck HER2-Positive Breast Cancer Major Business
Table 49. Merck HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 50. Merck SWOT Analysis
Table 51. Merck HER2-Positive Breast Cancer Product and Solutions
Table 52. Merck HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Roche Group Corporate Information, Location and Competitors
Table 54. Roche Group HER2-Positive Breast Cancer Major Business
Table 55. Roche Group HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 56. Roche Group SWOT Analysis
Table 57. Roche Group HER2-Positive Breast Cancer Product and Solutions
Table 58. Roche Group HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Radius Pharmaceuticals Corporate Information, Location and Competitors
Table 60. Radius Pharmaceuticals HER2-Positive Breast Cancer Major Business
Table 61. Radius Pharmaceuticals HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 62. Radius Pharmaceuticals SWOT Analysis
Table 63. Radius Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions
Table 64. Radius Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. GlaxoSmithKline Corporate Information, Location and Competitors
Table 66. GlaxoSmithKline HER2-Positive Breast Cancer Major Business
Table 67. GlaxoSmithKline HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 68. GlaxoSmithKline SWOT Analysis
Table 69. GlaxoSmithKline HER2-Positive Breast Cancer Product and Solutions
Table 70. GlaxoSmithKline HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Syndax Pharmaceuticals Corporate Information, Location and Competitors
Table 72. Syndax Pharmaceuticals HER2-Positive Breast Cancer Major Business
Table 73. Syndax Pharmaceuticals HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 74. Syndax Pharmaceuticals SWOT Analysis
Table 75. Syndax Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions
Table 76. Syndax Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Millennium Pharmaceuticals Corporate Information, Location and Competitors
Table 78. Millennium Pharmaceuticals HER2-Positive Breast Cancer Major Business
Table 79. Millennium Pharmaceuticals HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 80. Millennium Pharmaceuticals SWOT Analysis
Table 81. Millennium Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions
Table 82. Millennium Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Merrimack Pharmaceuticals Corporate Information, Location and Competitors
Table 84. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Major Business
Table 85. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 86. Merrimack Pharmaceuticals SWOT Analysis
Table 87. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions
Table 88. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Bayer Corporate Information, Location and Competitors
Table 90. Bayer HER2-Positive Breast Cancer Major Business
Table 91. Bayer HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 92. Bayer SWOT Analysis
Table 93. Bayer HER2-Positive Breast Cancer Product and Solutions
Table 94. Bayer HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Eagle Pharmaceuticals Corporate Information, Location and Competitors
Table 96. Eagle Pharmaceuticals HER2-Positive Breast Cancer Major Business
Table 97. Eagle Pharmaceuticals HER2-Positive Breast Cancer Total Revenue (USD Million) (2017-2018)
Table 98. Eagle Pharmaceuticals SWOT Analysis
Table 99. Eagle Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions
Table 100. Eagle Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Global HER2-Positive Breast Cancer Revenue (Million USD) by Players (2015-2020)
Table 102. Global HER2-Positive Breast Cancer Revenue Share by Players (2015-2020)
Table 103. Global HER2-Positive Breast Cancer Revenue (Million USD) by Regions (2015-2020)
Table 104. Global HER2-Positive Breast Cancer Revenue Market Share by Regions (2015-2020)
Table 105. North America HER2-Positive Breast Cancer Revenue by Countries (2015-2020)
Table 106. North America HER2-Positive Breast Cancer Revenue Market Share by Countries (2015-2020)
Table 107. Europe HER2-Positive Breast Cancer Revenue (Million USD) by Countries (2015-2020)
Table 108. Asia-Pacific HER2-Positive Breast Cancer Revenue (Million USD) by Countries (2015-2020)
Table 109. South America HER2-Positive Breast Cancer Revenue by Countries (2015-2020)
Table 110. South America HER2-Positive Breast Cancer Revenue Market Share by Countries (2015-2020)
Table 111. Middle East and Africa HER2-Positive Breast Cancer Revenue (Million USD) by Countries (2015-2020)
Table 112. Middle East and Africa HER2-Positive Breast Cancer Revenue Market Share by Countries (2015-2020)
Table 113. Global HER2-Positive Breast Cancer Revenue (Million USD) by Type (2015-2020)
Table 114. Global HER2-Positive Breast Cancer Revenue Share by Type (2015-2020)
Table 115. Global HER2-Positive Breast Cancer Revenue Forecast by Type (2021-2025)
Table 116. Global HER2-Positive Breast Cancer Revenue by Application (2015-2020)
Table 117. Global HER2-Positive Breast Cancer Revenue Share by Application (2015-2020)
Table 118. Global HER2-Positive Breast Cancer Revenue Forecast by Application (2021-2025)
Table 119. Global HER2-Positive Breast Cancer Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. HER2-Positive Breast Cancer Picture
Figure 2. Global HER2-Positive Breast Cancer Revenue Market Share by Type in 2019
Figure 3. Grifola Frondosa Picture
Figure 4. Surgery Picture
Figure 5. Radiation and Chemotherapy Picture
Figure 6. Endocrine Therapy Picture
Figure 7. Molecular Targeted Therapy Picture
Figure 8. HER2-Positive Breast Cancer Revenue Market Share by Application in 2019
Figure 9. Hospital Picture
Figure 10. Specialist Clinic Picture
Figure 11. Biotechnology and Pharmaceutical Companies Picture
Figure 12. Research and Academic Institutions Picture
Figure 13. Other Picture
Figure 14. Global HER2-Positive Breast Cancer Revenue (USD Million) and Growth Rate (2015-2025)
Figure 15. North America HER2-Positive Breast Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Europe HER2-Positive Breast Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Asia-Pacific HER2-Positive Breast Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. South America HER2-Positive Breast Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Middle East and Africa HER2-Positive Breast Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global HER2-Positive Breast Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global HER2-Positive Breast Cancer Revenue Share by Players in 2019
Figure 22. Global Top 5 Players HER2-Positive Breast Cancer Revenue Market Share in 2019
Figure 23. Global Top 10 Players HER2-Positive Breast Cancer Revenue Market Share in 2019
Figure 24. Key Players Market Share Trend
Figure 25. Global HER2-Positive Breast Cancer Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 26. Global HER2-Positive Breast Cancer Revenue Market Share by Regions (2015-2020)
Figure 27. Global HER2-Positive Breast Cancer Revenue Market Share by Regions in 2018
Figure 28. North America HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 29. Europe HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 30. Asia-Pacific HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 31. South America HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 32. Middle East and Africa HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 33. North America HER2-Positive Breast Cancer Revenue Market Share by Countries (2015-2020)
Figure 34. North America HER2-Positive Breast Cancer Revenue Market Share by Countries in 2019
Figure 35. USA HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 36. Canada HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 37. Mexico HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 38. Europe HER2-Positive Breast Cancer Revenue Market Share by Countries (2015-2020)
Figure 39. Europe HER2-Positive Breast Cancer Revenue Market Share by Countries in 2019
Figure 40. Germany HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 41. UK HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 42. France HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 43. Russia HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 44. Italy HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 45. Asia-Pacific HER2-Positive Breast Cancer Revenue Market Share by Countries (2015-2020)
Figure 46. Asia-Pacific HER2-Positive Breast Cancer Revenue Market Share by Countries in 2019
Figure 47. China HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 48. Japan HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 49. Korea HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 50. India HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 51. Southeast Asia HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 52. South America HER2-Positive Breast Cancer Revenue Market Share by Countries (2015-2020)
Figure 53. South America HER2-Positive Breast Cancer Revenue Market Share by Countries in 2019
Figure 54. Brazil HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 55. Argentina HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 56. Middle East and Africa HER2-Positive Breast Cancer Revenue Market Share by Countries (2015-2020)
Figure 57. Middle East and Africa HER2-Positive Breast Cancer Revenue Market Share by Countries in 2019
Figure 58. Saudi Arabia HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 59. UAE HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 60. Egypt HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 61. South Africa HER2-Positive Breast Cancer Revenue and Growth Rate (2015-2020)
Figure 62. Global HER2-Positive Breast Cancer Revenue Share by Type (2015-2020)
Figure 63. Global HER2-Positive Breast Cancer Revenue Share by Type in 2019
Figure 64. Global HER2-Positive Breast Cancer Market Share Forecast by Type (2021-2025)
Figure 65. Global Grifola Frondosa Revenue Growth Rate (2015-2020)
Figure 66. Global Surgery Revenue Growth Rate (2015-2020)
Figure 67. Global Radiation and Chemotherapy Revenue Growth Rate (2015-2020)
Figure 68. Global Endocrine Therapy Revenue Growth Rate (2015-2020)
Figure 69. Global Molecular Targeted Therapy Revenue Growth Rate (2015-2020)
Figure 70. Global HER2-Positive Breast Cancer Revenue Share by Application (2015-2020)
Figure 71. Global HER2-Positive Breast Cancer Revenue Share by Application in 2019
Figure 72. Global HER2-Positive Breast Cancer Market Share Forecast by Application (2021-2025)
Figure 73. Global Hospital Revenue Growth Rate (2015-2020)
Figure 74. Global Specialist Clinic Revenue Growth Rate (2015-2020)
Figure 75. Global Biotechnology and Pharmaceutical Companies Revenue Growth Rate (2015-2020)
Figure 76. Global Research and Academic Institutions Revenue Growth Rate (2015-2020)
Figure 77. Global Other Revenue Growth Rate (2015-2020)
Figure 78. Global HER2-Positive Breast Cancer Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 79. Global HER2-Positive Breast Cancer Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 80. Global HER2-Positive Breast Cancer Revenue Market Share Forecast by Regions (2021-2025)
Figure 81. North America HER2-Positive Breast Cancer Revenue Market Forecast (2021-2025)
Figure 82. Europe HER2-Positive Breast Cancer Revenue Market Forecast (2021-2025)
Figure 83. Asia-Pacific HER2-Positive Breast Cancer Revenue Market Forecast (2021-2025)
Figure 84. South America HER2-Positive Breast Cancer Revenue Market Forecast (2021-2025)
Figure 85. Middle East and Africa HER2-Positive Breast Cancer Revenue Market Forecast (2021-2025)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel
乳がん治療薬の世界市場 2020年 Market Overview The global Breast Cancer Treatment Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Breast Cancer T…- 乳がんスクリーニングの世界市場 2020年 Market Overview The Breast Cancer Screening market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…
- 乳がん診断技術の世界市場 2020年 Market Overview The global Breast Cancer Diagnostic Technologies market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Breast …
- 容積式ポンプの世界市場 2020年 Market Overview The global Positive Displacement Pumps market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.5% in the forecast period of 2020 to 2025 and will expected to reach USD 10780 million by 2025, from USD 9384 million in 2019. The Positive Di…
- 実験室における容積式ピペットの世界市場 2020年 Market Overview The global Positive Displacement Pipettes in Laboratory market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The …